For example, Prahallad et al. (2012) showed that vemurafenib is highly effective in the treatment of melanoma in patients with BRAF(V600E) mutation while colon cancer patients harboring the same BRAF(V600E) mutation have a very limited response to this drug. This evidence concerns the gene BRAF and malignant colon neoplasm.